TABLE 3.
Summary half-life and AUC of dose in plasma and RBC of present and prior study1
| AUC |
t1/2 |
|||
| Plasma | RBC | Plasma | RBC | |
| % dose/L·d | d | |||
| Nonextrapolated | ||||
| 0–2 d, 0-t | 8.78 ± 2.68 | 2.49 ± 0.58 | 0.78 ± 0.07 | 0.87 ± 0.07 |
| 0–4 d, 0-t | 11.9 ± 3.3 | 3.62 ± 0.85 | 1.12 ± 0.09 | 1.26 ± 0.10 |
| 0–5 d, 0-t | 13.3 ± 3.7 | 4.32 ± 1.01 | 1.32 ± 0.07 | 1.50 ± 0.17 |
| 0–70 d, 0-t | 24.2 ± 7.5 | 14.6 ± 3.6 | 7.46 ± 0.50 | 15.2 ± 3.0 |
| 0–460 d, 0-t | 36.7 ± 9.5 | 42.4 ± 21.5 | 44.0 ± 12.0 | 95.7 ± 41.9 |
| Extrapolated | ||||
| 0–2 d, 0-∞ | 17.1 ± 6.0 | 5.52 ± 2.04 | 2.18 ± 0.66 | 2.64 ± 0.78 |
| Prior study (21) | 1.79 ± 0.88 | 2.13 ± 0.58 | ||
| Prior study (20) | 2.15 ± 0.73 | |||
| 0–4 d, 0-∞ | 15.8 ± 4.7 | 5.44 ± 1.03 | 1.95 ± 0.21 | 2.47 ± 0.46 |
| Prior study (23) | 3.36 ± 0.80 | 9.3 ± 2.37 | ||
| Prior study (22) | 1.83 ± 0.78 | |||
| 0–5 d, 0-∞ | 16.9 ± 5.3 | 5.56 ± 1.30 | 2.24 ± 0.26 | 2.48 ± 0.49 |
| 0–70 d, 0-∞ | 27.6 ± 8.4 | 32.9 ± 18.0 | 18.3 ± 5.2 | 96.2 ± 80.6 |
| 0–460 d, 0-∞ | 41.6 ± 10.7 | 63.8 ± 47.0 | 105 ± 67 | 217 ± 123 |
1
Values are mean ± SD, = 12.